Peace Of Mind Accuracy

• The Eversense^® E3 Sensor uses fluorescent light technology to measure glucose in interstitial fluid.
  
  
• The intensity of the fluorescent light signal rises and falls in proportion to the body’s glucose levels
  
  
• There is no interference with glucose measurements from Vitamin C or acetaminophen.

• The overall MARD of the Eversense^® E3 CGM system is 8.5% with 87.3% of readings within 15 mg/dL or 15% of the reference values (YSI).
  
  
• In the hypoglycaemic range (40–60 mg/dL) the MAD* gets even better at 7.5% with 91.6% of readings within 15/15.

Month by month, Eversense E3 has demonstrated exceptional accuracy and stable performance over the course of 180 days with a single sensor. Readings you can count on!

• 94% of low glucose events were detected correctly and alerted (using Predictive Alert), comparing to the laboratory reference (YSI)
  
  
• 99% of high glucose events were detected correctly and alerted (using Predictive Alert), comparing to the laboratory reference (YSI)
  
  
• Maybe it’s time to consider activating the Predictive Alert feature in the Eversense App. Talk to your health care provider to help you with this setting

* MAD (mg/dL) was calculated for glucose values ≤ 80 mg/dL.
1. Garg, S. K. et al. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1-9. DOI: 10.1089/dia.2021.0182